ABSTRACT
BACKGROUND: Parainfluenza virus (PIV), a common pediatric pathogen, is associated with significant morbidity in immunocompromised (IC) hosts. DAS181, a novel sialidase fusion protein inhibitor, seems to be effective against PIV in vitro and in vivo; its use in IC children has not been evaluated. METHODS: Patients were diagnosed with PIV infection using a quantitative reverse transcription-polymerase chain reaction. DAS181 was obtained under emergency investigational new drug applications and was administered via aerosol chamber or nebulizer. Patients were assessed daily for their clinical condition and adverse outcomes. RESULTS: Four pediatric hematopoietic cell transplantation (HCT) patients with PIV detected in respiratory specimens were identified and treated with DAS 181. Patients 1 and 2 were diagnosed with PIV lower respiratory tract infection (LRTI) by bronchoalveolar lavage at 9 months and 2 days after allogeneic transplantation, respectively. Patient 3 was on chemotherapy prior to planned autologous HCT at time of PIV diagnosis from a nasal swab. Patient 4 was diagnosed with PIV via nasal wash 2 days after HCT. Patients 1-3 had clinical symptoms and chest imaging consistent with LRTI. Inhaled DAS181 was administered for 5-10 days. All 4 patients tolerated therapy well. Clinical improvement in oxygen requirement and respiratory rate was observed in all patients who required oxygen at therapy initiation. Viral load decreased in all patients within 1 week of therapy and became undetectable by day 3 of therapy in patient 3. CONCLUSION: DAS181 was used to treat 4 severely IC pediatric patients with PIV disease. The drug was well tolerated. Improvement in both viral loads and symptoms after initiation of therapy was observed in all cases. This report supports prospective, randomized studies in IC patients with PIV infection.
Subject(s)
Immunocompromised Host/physiology , Parainfluenza Virus 2, Human/drug effects , Parainfluenza Virus 3, Human/drug effects , Recombinant Fusion Proteins/pharmacology , Recombinant Fusion Proteins/therapeutic use , Respiratory Tract Infections/drug therapy , Respirovirus Infections/drug therapy , Rubulavirus Infections/drug therapy , Alanine Transaminase/blood , Alanine Transaminase/drug effects , Aspartate Aminotransferases/blood , Aspartate Aminotransferases/drug effects , Child , Child, Preschool , Humans , Infant , Leukemia, Myeloid, Acute/complications , Male , Neuroblastoma/complications , Parainfluenza Virus 2, Human/physiology , Parainfluenza Virus 3, Human/physiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Prospective Studies , Random Allocation , Recombinant Fusion Proteins/administration & dosage , Respiratory Tract Infections/diagnosis , Severe Combined Immunodeficiency/complications , Transplantation/adverse effects , Viral Load/drug effects , Viral Load/physiologyABSTRACT
Human parainfluenza virus (HPIV) infection as an aetiology of acute viral myocarditis is rare, with only few cases reported in the literature to date. Here we report a case of fulminant HPIV-2 myocarditis in a 47 year-old man with viraemia who was successfully treated with intravenous ribavirin and intravenous immunoglobulin (IVIG). There are currently no recommendations on the treatment of HPIV myocarditis. We are, to our knowledge, the first to report a patient with a documented HPIV-2 viraemia that subsequently cleared after the initiation of antiviral therapy. Although it is difficult to definitively attribute the patient's clinical improvement to ribavirin or IVIG alone, our case does suggest that clinicians may wish to consider initiating ribavirin and IVIG in patients with HPIV myocarditis and persistent viraemia not responding to supportive measures alone.
Subject(s)
Antiviral Agents/administration & dosage , Immunoglobulins, Intravenous/administration & dosage , Myocarditis/drug therapy , Parainfluenza Virus 2, Human/isolation & purification , Ribavirin/administration & dosage , Rubulavirus Infections/complications , Rubulavirus Infections/drug therapy , Administration, Intravenous , Humans , Male , Middle Aged , Molecular Sequence Data , Myocarditis/virology , RNA, Viral/genetics , Rubulavirus Infections/virology , Sequence Analysis, DNA , Treatment OutcomeSubject(s)
Bone Marrow Transplantation , Parainfluenza Virus 3, Human/pathogenicity , Parainfluenza Virus 4, Human/pathogenicity , Respiratory Tract Infections/virology , Respirovirus Infections/virology , Rubulavirus Infections/virology , Antiviral Agents/therapeutic use , Child , Cross Infection/transmission , Diagnosis, Differential , Humans , Immunocompromised Host , Parainfluenza Virus 4, Human/isolation & purification , Respiratory Tract Infections/drug therapy , Respirovirus Infections/diagnosis , Respirovirus Infections/drug therapy , Respirovirus Infections/transmission , Reverse Transcriptase Polymerase Chain Reaction , Ribavirin/therapeutic use , Rubulavirus Infections/diagnosis , Rubulavirus Infections/drug therapy , Rubulavirus Infections/transmission , VirulenceABSTRACT
Human parainfluenza type 2 virus (hPIV-2)-infected HeLa (HeLa-CA) cells and hPIV-2 V-expressing HeLa (HeLa-V) cells show high resistance to alpha/beta interferons (IFN-alpha/beta) irrespective of whether vesicular stomatitis virus or Sindbis virus is used as a challenge virus. When Sindbis virus is used, these cells show high susceptibility to human IFN-gamma. Furthermore, the multiplication of HeLa-V cells is not inhibited by IFN-alpha/beta. HeLa cells expressing the N-terminally truncated V protein show resistance to IFN-alpha/beta, showing that the IFN resistance determinant maps to the cysteine-rich V-specific domain. A complete defect of Stat2 is found in HeLa-CA and HeLa-V cells, whereas the levels of Stat1 expression are not significantly different among HeLa, HeLa-CA, HeLa-P, and HeLa-V cells, indicating that IFN-alpha/beta resistance of HeLa-CA and HeLa-V cells is due to a defect of Stat2. HeLa-SV41V cells show high resistance to all IFNs, and no expression of Stat1 can be detected. Stat2 mRNA is fully detected in HeLa-V cells. Stat2 was scarcely pulse-labeled in the HeLa-V cells, indicating that synthesis of Stat2 is suppressed or Stat2 is very rapidly degraded in HeLa-V cells. The V protein suppresses the in vitro translation of Stat2 mRNA more extensively than that of Stat1 mRNA. An extremely small amount of Stat2 can be detected in HeLa-V cells treated with proteasome inhibitors. The half-life of Stat2 is approximately 3.5 and 2 h in uninfected and hPIV-2-infected HeLa cells, respectively. This study shows that synthesis of Stat2 may be suppressed and Stat2 degradation is also enhanced in hPIV-2-infected HeLa and HeLa-V cells.